The company said, “For 2026, Dexcom (DXCM) currently anticipates total revenue of $5.16 – $5.25 billion, representing expected growth of approximately 11-13% over 2025. This outlook considers sensor volume growth driven by increasing CGM awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $86 from $84 at Bernstein
- Dexcom: Reset Expectations, Strengthened Fundamentals, and Operating Leverage Support Reiterated Buy Rating
- DexCom call volume above normal and directionally bullish
- Dexcom Names Jacob Leach as Incoming Chief Executive
- Claims Jabil losing share at Dexcom ‘not happening,’ says Raymond James